JP2022512684A5 - - Google Patents

Info

Publication number
JP2022512684A5
JP2022512684A5 JP2021520197A JP2021520197A JP2022512684A5 JP 2022512684 A5 JP2022512684 A5 JP 2022512684A5 JP 2021520197 A JP2021520197 A JP 2021520197A JP 2021520197 A JP2021520197 A JP 2021520197A JP 2022512684 A5 JP2022512684 A5 JP 2022512684A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
polypeptide construct
construct according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021520197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512684A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/055427 external-priority patent/WO2020076970A1/en
Publication of JP2022512684A publication Critical patent/JP2022512684A/ja
Publication of JP2022512684A5 publication Critical patent/JP2022512684A5/ja
Priority to JP2024148159A priority Critical patent/JP2024167342A/ja
Ceased legal-status Critical Current

Links

JP2021520197A 2018-10-11 2019-10-09 B7h3シングルドメイン抗体およびその治療用組成物 Ceased JP2022512684A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024148159A JP2024167342A (ja) 2018-10-11 2024-08-30 B7h3シングルドメイン抗体およびその治療用組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862744640P 2018-10-11 2018-10-11
US62/744,640 2018-10-11
US201962832274P 2019-04-10 2019-04-10
US62/832,274 2019-04-10
US201962877812P 2019-07-23 2019-07-23
US62/877,812 2019-07-23
PCT/US2019/055427 WO2020076970A1 (en) 2018-10-11 2019-10-09 B7h3 single domain antibodies and therapeutic compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024148159A Division JP2024167342A (ja) 2018-10-11 2024-08-30 B7h3シングルドメイン抗体およびその治療用組成物

Publications (2)

Publication Number Publication Date
JP2022512684A JP2022512684A (ja) 2022-02-07
JP2022512684A5 true JP2022512684A5 (https=) 2022-10-17

Family

ID=68318988

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021520197A Ceased JP2022512684A (ja) 2018-10-11 2019-10-09 B7h3シングルドメイン抗体およびその治療用組成物
JP2024148159A Pending JP2024167342A (ja) 2018-10-11 2024-08-30 B7h3シングルドメイン抗体およびその治療用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024148159A Pending JP2024167342A (ja) 2018-10-11 2024-08-30 B7h3シングルドメイン抗体およびその治療用組成物

Country Status (7)

Country Link
US (1) US20230124851A1 (https=)
EP (1) EP3864044A1 (https=)
JP (2) JP2022512684A (https=)
CN (1) CN113166261A (https=)
CA (1) CA3115082A1 (https=)
TW (1) TW202028246A (https=)
WO (1) WO2020076970A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
EP3827019A1 (en) 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Dll3シングルドメイン抗体およびその治療用組成物
JP2022504802A (ja) 2018-10-11 2022-01-13 インヒブルクス インコーポレイテッド 5t4シングルドメイン抗体およびその治療組成物
JP7789002B2 (ja) * 2020-01-29 2025-12-19 インヒブルクス バイオサイエンシズ インコーポレイテッド Cd28シングルドメイン抗体ならびにその多価および多重特異性の構築物
US20230303698A1 (en) * 2020-06-30 2023-09-28 Harbour Biomed (Shanghai) Co., Ltd Multispecific binding protein of immune cell engager, preparation therefor and application thereof
CN115667316A (zh) * 2020-06-30 2023-01-31 和铂医药(上海)有限责任公司 Fab-HCAb结构的结合蛋白
JP7620780B2 (ja) * 2020-06-30 2025-01-24 ノナ・バイオサイエンシーズ・(シャンハイ)・カンパニー・リミテッド H2L2とHCAb構造を有する結合タンパク質
CN111662384B (zh) 2020-06-30 2021-04-09 广州百暨基因科技有限公司 抗b7h3抗体及其应用
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
WO2022200525A1 (en) 2021-03-26 2022-09-29 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
AU2022253611B2 (en) * 2021-04-06 2026-04-09 Unicet Biotech Co. Llc METHODS TO IMPROVE STABILITY OF VIRUS TRANSDUCTION OF γδ T CELLS AND APPLICATIONS THEREOF
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
EP4365203A4 (en) * 2021-07-01 2025-09-24 Ningbo T Maximum Biopharmaceuticals Co Ltd ANTIGEN-BINDING POLYPEPTIDE TARGETING B7H3 AND ITS APPLICATION
US20240417469A1 (en) * 2021-10-12 2024-12-19 Concept To Medicine Biotech Co., Ltd. Cd3-targeting t-cell engagers with improved therapeutic index
CN113980143B (zh) * 2021-11-02 2023-04-25 深圳先进技术研究院 靶向cd276的嵌合抗原受体、嵌合抗原受体t细胞及制备方法和制药应用
JPWO2023100944A1 (https=) * 2021-12-01 2023-06-08
US12365743B2 (en) 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
WO2024035342A1 (en) * 2022-08-08 2024-02-15 Tessa Therapeutics Ltd B7-h3 antigen-binding molecules
WO2024061297A1 (en) * 2022-09-22 2024-03-28 Shanghai Henlius Biotech , Inc. Anti-b7h3 antibodies, multispecific antibodies and methods of use
KR20250075604A (ko) * 2022-09-22 2025-05-28 상하이 헨리우스 바이오테크, 인크. 항-b7h3 항체 및 사용 방법
WO2024140925A1 (en) * 2022-12-29 2024-07-04 Beigene, Ltd. Anti-b7h3 antibodies and methods of use
WO2024140932A1 (en) * 2022-12-29 2024-07-04 Beigene, Ltd. Anti-b7h3 antibodies and methods of use
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
CN118829656B (zh) * 2023-12-01 2026-04-24 苏州智核生物医药科技有限公司 B7h3结合多肽及其用途
TW202528354A (zh) * 2024-01-03 2025-07-16 中國商北京泰德製藥股份有限公司 B7-h3結合蛋白及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025157244A1 (zh) * 2024-01-25 2025-07-31 山东先声生物制药有限公司 抗b7h3抗体及其应用
CN118702816B (zh) * 2024-06-03 2025-03-28 内蒙古正德缘生物科技有限责任公司 一种nk细胞及其在抗肿瘤治疗中的应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3414831A1 (de) 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
DE3536939A1 (de) 1985-10-17 1987-04-23 Hoechst Ag Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE4036856C1 (https=) 1990-11-19 1992-05-27 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5770191A (en) 1995-05-24 1998-06-23 University Of Florida Active C-terminal peptides of interferon--gamma and their use
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
EP1002861A1 (en) 1998-10-26 2000-05-24 Unilever Plc Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
FR2822845B1 (fr) 2001-03-30 2003-12-12 Genodyssee Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823763A1 (fr) 2001-04-18 2002-10-25 Genodyssee Nouveaux polynucleotides et polypeptides de l'interferon alpha 6
FR2823764B1 (fr) 2001-04-24 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides du gene ifn alpha-17
FR2824333B1 (fr) 2001-05-03 2003-08-08 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 5
FR2825102B1 (fr) 2001-05-23 2003-08-29 Genodyssee Nouveaux polynucleotides et polypeptides de l'interferon alpha 14
FR2825716B1 (fr) 2001-06-11 2004-09-24 Genodyssee Nouveaux polynucleotides et polypeptides de l'ifn alpha 7
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
DE60332358D1 (de) 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
AU2003267700A1 (en) 2002-09-09 2004-03-29 Nautilus Biotech Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP3803790B2 (ja) 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
CN101309703A (zh) 2005-09-12 2008-11-19 诺维莫尼公司 抗cd3抗体组合物
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
EP2225277A4 (en) 2007-11-27 2012-03-14 Viventia Biotech Inc ANTIBODIES TO A CANCER-ASSOCIATED EPITOPE OF THE VARIANT NFKBIB AND APPLICATIONS THEREOF
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
RU2636046C2 (ru) 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
WO2012147713A1 (ja) * 2011-04-25 2012-11-01 第一三共株式会社 抗b7-h3抗体
KR102060389B1 (ko) * 2011-05-21 2019-12-31 마크로제닉스, 인크. 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
AU2013322710A1 (en) 2012-09-25 2015-04-16 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
EP2914634B1 (en) 2012-11-02 2017-12-06 Zymeworks Inc. Crystal structures of heterodimeric fc domains
JP6385357B2 (ja) 2012-11-27 2018-09-05 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションAjou University Industry−Academic Cooperation Foundation 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するch3ドメイン変異体対、その作製方法および用途
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US9703815B2 (en) 2012-12-17 2017-07-11 Salesforce.Com, Inc. Third party files in an on-demand database service
TW201427989A (zh) 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
JP6594855B2 (ja) 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
ME03675B (me) 2013-07-05 2020-10-20 Genmab As Humanizovana ili himerna anтi-cd3 antiтela
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
NZ718283A (en) 2013-09-25 2022-05-27 Cytomx Therapeutics Inc Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
IL263466B2 (en) 2013-12-17 2023-10-01 Genentech Inc Anti-CD3 antibodies and methods of using them
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
US9562073B2 (en) 2014-01-31 2017-02-07 Cytomx Therapeutics, Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
EP3149040A1 (en) * 2014-05-29 2017-04-05 Spring Bioscience Corporation Anti-b7-h3 antibodies and diagnostic uses thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP4205749A1 (en) * 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
KR102485788B1 (ko) * 2014-08-27 2023-01-09 메모리얼 슬로안 케터링 캔서 센터 항체, 조성물 및 용도
PE20171324A1 (es) * 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
WO2016087650A1 (en) 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
JP7001474B2 (ja) 2015-01-21 2022-01-19 インヒブルクス,インコーポレイティド 非免疫原性単一ドメイン抗体
WO2016192613A1 (zh) * 2015-06-01 2016-12-08 中山大学 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
EP3916018A1 (en) 2015-06-16 2021-12-01 Genentech, Inc. Anti-cd3 antibodies and methods of use
MX2018000948A (es) 2015-07-23 2018-09-27 Inhibrx Inc Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
US20190002563A1 (en) 2015-08-17 2019-01-03 Macrogenics, Inc. Bispecific Monovalent Diabodies That are Capable of Binding B7-H3 and CD3, and Uses Thereof
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
IL300122A (en) * 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
KR20180098671A (ko) 2016-01-11 2018-09-04 인히브릭스, 인크. 다가 및 다중특이적 ox40-결합 융합 단백질
KR20180096789A (ko) 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
GB201602156D0 (en) 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018027025A1 (en) 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN109843927B (zh) * 2017-03-06 2022-06-21 江苏恒瑞医药股份有限公司 抗b7-h3抗体、其抗原结合片段及其医药用途
JP2021508479A (ja) 2017-12-27 2021-03-11 テネオバイオ, インコーポレイテッド ヘテロ二量体特異的抗体上のcd3デルタ及びcd3イプシロン
KR20260046525A (ko) * 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도

Similar Documents

Publication Publication Date Title
JP2022512684A5 (https=)
JP2022504802A5 (https=)
JP2022512653A5 (https=)
JP2022504822A5 (https=)
AU2025202388A1 (en) CD3-targeting antibody, bispecific antibody and use thereof
JP2019525738A5 (https=)
JP2012501670A5 (https=)
JP2020508655A5 (https=)
JP2020517287A5 (https=)
JP2022541435A5 (https=)
JP2021098732A5 (https=)
JP2018522888A5 (https=)
RU2021111382A (ru) Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
JP2019513370A5 (https=)
JP2020525032A5 (https=)
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
JP2024023228A5 (https=)
JP2022514693A5 (https=)
JP2016536322A5 (https=)
JP2018503380A5 (https=)
RU2020142965A (ru) Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
JP2012501669A5 (https=)
JP2017520575A5 (https=)
JP2022545647A5 (https=)
CA3139508A1 (en) Materials and methods for modulating t cell mediated immunity